Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Iakov I Davydov

Showing results (11-20 of 14) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 14 results.
Nature Medicine|April 20, 2026
Cibisatamab and FAP-4-1BBL in microsatellite-stable colorectal cancer: a phase 1b trialIgnacio Melero, Tamara Tanos, Emiliano Calvo Aller, et al.
Science Translational Medicine|May 10, 2023
A first-in-human study of the fibroblast activation protein-targeted, 4-1BB agonist RO7122290 in patients with advanced solid tumorsIgnacio Melero, Tamara Tanos, Mariana Bustamante, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 13, 2026
A Randomized, Nivolumab-controlled, Phase 2 and Biomarker Study of Lomvastomig and Tobemstomig in Advanced or Metastatic Squamous Cell Carcinoma of the EsophagusLucjan Wyrwicz, Arunee Dechaphunkul, Jong-Seok Lee, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 7, 2026
A first-in-human phase 1 clinical trial evaluating clinical activity and proof-of-mechanism of tobemstomig, a PD1-LAG3 bispecific antibody, in patients with CPI-experienced melanomaElena Garralda, Christoph Markert, Victor Moreno, et al.
Pageof 2

Showing results (11-20 of 14) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 14 results.
Nature Medicine|April 20, 2026
Cibisatamab and FAP-4-1BBL in microsatellite-stable colorectal cancer: a phase 1b trialIgnacio Melero, Tamara Tanos, Emiliano Calvo Aller, et al.
Science Translational Medicine|May 10, 2023
A first-in-human study of the fibroblast activation protein-targeted, 4-1BB agonist RO7122290 in patients with advanced solid tumorsIgnacio Melero, Tamara Tanos, Mariana Bustamante, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 13, 2026
A Randomized, Nivolumab-controlled, Phase 2 and Biomarker Study of Lomvastomig and Tobemstomig in Advanced or Metastatic Squamous Cell Carcinoma of the EsophagusLucjan Wyrwicz, Arunee Dechaphunkul, Jong-Seok Lee, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 7, 2026
A first-in-human phase 1 clinical trial evaluating clinical activity and proof-of-mechanism of tobemstomig, a PD1-LAG3 bispecific antibody, in patients with CPI-experienced melanomaElena Garralda, Christoph Markert, Victor Moreno, et al.
Pageof 2